Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for DENILEUKIN DIFTITOX
- T-regulatory Cell Depletion With E7777 Combined With Pembrolizumab in Recurrent or Metastatic Solid Tumors
- Ipilimumab Administered to Stage IIIC Stage IV Melanoma After Reg. T Cell Depletion With Denileukin Diftitox
- A Trial of Intravenous Denileukin Diftitox Plus Subcutaneous Pegylated IFNα-2A in Stage III or IV Ovarian Cancer
- Access Program With Denileukin Diftitox for the Treatment of Patients Currently Receiving Treatment With Commercially Available (Ontak)
- Dose Escalation Trial of Denileukin Diftitox (Ontak) Post Autologous Transplantation
- Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma
- Haploidentical Natural Killer Cells to Treat Refractory or Relapsed Acute Myelogenous Leukemia (AML)
- Acute Graft-versus-Host Disease Treatment (BMT CTN 0802)
- A Trial of Intravenous Denileukin Diftitox in Stage III or IV Ovarian Cancer
- Denileukine Diftitox for Relapsed ALCL
- A Pilot Study, Evaluating the Efficacy of Regulatory T-cell Suppression by Ontak in Metastatic Pancreatic Cancer
- Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak)
- Rituximab for GVHD
- Combination Chemotherapy and Denileukin Diftitox in Treating Patients With Newly Diagnosed T-Cell Non-Hodgkin Lymphoma
- Ontak (Denileukin Diftitox) in Patients With Systemic Mastocytosis (SM)
- Combination Daclizumab/Denileukin Diftitox to Treat Uveitis
- Phase II Trial of Ontak With Metastatic Melanoma
- Cyclophosphamide or Denileukin Diftitox Followed By Expanding a Patient's Own T Cells in the Laboratory in Treating Patients With HER-2/Neu Overexpressing Metastatic Breast Cancer, Ovarian Cancer, or Non-Small Cell Lung Cancer Previously Treated Wit
- Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
- Lymphocytic B-Leukemia (B-CLL) w/Human IL-2 Gene Modified & Human CD40 Ligand-Expressing Autologous Tumor Cells
- A Study of ONTAK in Patients With Relapsed or Refractory, B-Cell Non Hodgkin's Lymphoma
- Study of ONTAK® to Treat Cutaneous T-Cell Lymphoma (CTCL)
- A Study of ONTAK and CHOP in Newly Diagnosed, Peripheral T-Cell Lymphoma
- Study of ONTAK in Patients With B-Cell Chronic Lymphocytic Leukemia (CLL)
- Phase II Study of ONTAK in Previously Treated Patients With Low-grade Non-Hodgkin's Lymphoma (NHL)
- Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients
- Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) Patients
- Blood and Marrow Transplant Clinical Research Network
- Dexamethasone Followed by Denileukin Diftitox in Treating Patients With Persistent or Recurrent T-Cell Lymphoma
Clinical trials list
click for details